Chemical Starting Matter for HNF4α Ligand Discovery and Chemogenomics

Isabelle Meijer 1, Sabine Willems 1, Xiaomin Ni 1,2, Jan Heering 3, Apirat Chaikuad 1,2* and Daniel Merk 1,*

1 Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt, Germany; a01568041@unet.univie.ac.at (I.M.); willems@pharmchem.uni-frankfurt.de (S.W.); ni@em.uni-frankfurt.de (X.N.); chaikuad@pharmchem.uni-frankfurt.de (A.C.)

2 Structural Genomics Consortium, BMLS, Goethe-University Frankfurt, Max-von-Laue-Str. 15, 60438 Frankfurt, Germany

3 Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Branch for Translational Medicine and Pharmacology TMP, Theodor-Stern-Kai 7, 60596 Frankfurt, Germany; Jan.Heering@ime.fraunhofer.de

* Correspondence: merk@pharmchem.uni-frankfurt.de

Received: 14 September 2020; Accepted: 21 October 2020; Published: 24 October 2020

Abstract: Hepatocyte nuclear factor 4α (HNF4α) is a ligand-sensing transcription factor and presents as a potential drug target in metabolic diseases and cancer. In humans, mutations in the HNF4α gene cause maturity-onset diabetes of the young (MODY), and the elevated activity of this protein has been associated with gastrointestinal cancers. Despite the high therapeutic potential, available ligands and structure–activity relationship knowledge for this nuclear receptor are scarce. Here, we disclose a chemically diverse collection of orthogonally validated fragment-like activators as well as inverse agonists, which modulate HNF4α activity in a low micromolar range. These compounds demonstrate the druggability of HNF4α and thus provide a starting point for medicinal chemistry as well as an early tool for chemogenomics.

Keywords: Orphan nuclear receptor; hepatocyte nuclear factor 4α; MODY; type 2 diabetes; fragment-based design; drug discovery

1. Introduction

The transcriptional regulator hepatocyte nuclear factor 4α (HNF4α, NR2A1) [1,2] belongs to the protein family of nuclear receptors which are ligand-sensing transcription factors. HNF4α acts as an obligate homodimer [3] and has constitutive transactivation activity [1]. It was initially considered as an orphan nuclear receptor [1,2] prior to the identification of linoleic acid as a potential endogenous ligand, whose binding, however, has been reported to hardly affect the receptor’s transcriptional activity [4]. HNF4α is mainly found in hepatocytes, enterocytes, and pancreatic β-cells [5,6], and exhibits key regulatory roles in intestine [7], liver [8], and pancreas [9]. Its dysregulation has been associated with gastrointestinal and metabolic diseases [5,10,11] as well as gastrointestinal cancers [5,12,13]. Mutations within the HNF4α gene cause the heritable form of type 2 diabetes, maturity-onset diabetes of the young 1 (MODY-1) [10,14–16], highlighting the receptor’s crucial role in metabolic homeostasis. Despite an attractive potential for pharmacological interventions in diabetes or cancer, the collection of ligands that can modulate the transcriptional activity of HNF4α is scarce. Kiselyuk et al. [5] have previously reported antagonists of HNF4α with low micromolar potencies that decreased the receptor levels as well as expression of the targeted genes in cellular settings. In addition, a series of naphthofuranones [17] was found to bind the HNF4α ligand-binding domain (LBD) and enhance the receptor’s transcriptional
activity. While these important observations demonstrate the possibility of HNF4α modulation with small molecules, novel HNF4α ligands are needed to overcome the limited potency, physicochemical restrictions, and lack of chemical diversity of available HNF4α modulators.

To expand the collection of HNF4α ligands, we screened a collection of 480 drug fragments for HNF4α modulation in a cellular setting. Dose-response profiling, control experiments, effects on HNF4α-regulated gene expression in native cellular setting, and interaction studies with the recombinant HNF4α LBD fully confirmed a set of appealing molecules as HNF4α modulators including agonists and inverse agonists. The most active compounds modulated the orphan nuclear receptor with low micromolar potencies and modulated mRNA expression of the HNF4α-regulated gene fructose-1,6-bisphosphatase 1 (FBP1) in human hepatocytes. For three HNF4α modulators, isothermal titration confirmed direct binding to the recombinant HNF4α LBD with micromolar affinities. This set of chemically diverse HNF4α ligands will serve as a starting point for medicinal chemistry, enabling the development of tool compounds for further pharmacological studies on the role of HNF4α in diseases.

2. Results

2.1. Primary Screening

To search for new modulators of HNF4α activity without previous knowledge on the structure–activity relationship of HNF4α ligands, we screened a collection of 480 fragments derived from FDA approved drugs for their abilities to modulate HNF4α activity in vitro (the fragment structures contained in the library and associated primary screening data are provided as Table S1). This library was chemically diverse in terms of feature distribution (Figure 1) and scaffolds, providing an attractive unbiased and economic entry to HNF4α ligand discovery.

For the primary screening system, we employed a hybrid Gal4 reporter gene assay in transiently transfected HEK293T cells. Therein, a Gal4 responsive firefly luciferase construct served as a reporter gene to determine the transcriptional activity of a hybrid receptor composed of the human HNF4α LBD and the DNA-binding domain of Gal4 from yeast. A constitutively active (SV40 promoter) renilla luciferase construct was additionally present to monitor the transfection efficiency and toxicity of test compounds. This system is advantageous as it captures various characteristics of nuclear receptor modulators including potency, type of activity, efficacy, and cell permeability [18]. In accordance with previous reports on the behavior of HNF4α [1], the chimeric Gal4-HNF4α receptor revealed marked constitutive transcriptional activity in the absence of ligands.

The entire fragment library was tested for Gal4-HNF4α modulation using this primary screening assay, which was performed in two biologically independent repeats using compounds at 50 µM concentration. Reporter activity for the entire fragment set was narrowly distributed with a mean of 1.09 and a standard deviation of 0.43. Fragments exhibiting a fold activation outside the mean ± SD region were evaluated as primary hits. Eighteen fragments induced reporter activity to values above 1.52-fold activation (mean + SD) and were considered as potential agonists. Five compounds suppressed the
reporter signal to values below 0.67-fold activation (mean - SD) and were considered as potential inverse agonists (Figure 2). The primary hits were then manually curated for toxic compounds (as observed by effects on constitutively active renilla luciferase) and undesired structures (PAINS), leaving a primary hit collection of eleven fragments (1-11) for validation (Table 1). This primary hit list comprised eight potential HNF4α activators (1-8) and three inverse agonist candidates (9-11).

![Figure 2](image-url)  
**Figure 2.** Activity distribution and primary hits in the fragment screening. Red line shows the mean, dotted red lines show mean ± SD. Each point represents the activity of one fragment at 50 µM expressed as mean fold activation vs. 0.2% DMSO from two biologically independent repeats. Green crosses refer to HNF4α agonist candidates, yellow crosses refer to inverse HNF4α agonist candidates, blue dots represent fragments without activity on Gal4-HNF4α.

| ID | Structure | Primary Screen (Fold Act., 50 µM) | Follow-up HNF4α | VP16 Control | HNF4α vs. VP16 |
|----|-----------|-----------------------------------|------------------|--------------|----------------|
| 1  | ![Structure 1](image-url) | 2.48 | 1.1 ± 0.2 (50 µM) | 0.80 ± 0.07 (50 µM) | n.s. |
| 2  | ![Structure 2](image-url) | 1.55 | 1.3 ± 0.2 (50 µM) | 1.3 ± 0.3 (50 µM) | n.s. |
| 3  | ![Structure 3](image-url) | 2.09 | 1.5 ± 0.2 (50 µM) | 1.7 ± 0.3 (50 µM) | n.s. |
| 4  | ![Structure 4](image-url) | 5.18 | 4 ± 2 (50 µM) | 0.5 ± 0.2 (50 µM) | \( p = 0.0014 \) (**) |
| 5  | ![Structure 5](image-url) | 1.80 | 2.5 ± 0.2 (100 µM) | 1.1 ± 0.1 (100 µM) | \( p < 0.0001 \) (***)) |

**Table 1.** Primary screening hits with primary screening data and control experiment on VP16 for non-specific activity. Primary screening data are the mean of two biologically independent repeats. HNF4α follow-up data and VP16 control data are the mean ± SD fold activation of reporter activity of at least four biologically independent repeats in duplicates. n.s.—not significant \( (p \geq 0.05) \), ** \( p < 0.01 \), *** \( p < 0.001 \) (t-test).
2. Hit Validation

HNF4α modulation of the primary screening hits 1–11 was subsequently reproduced with fresh material in four biologically independent repeats in duplicates. For compounds exhibiting pronounced toxicity at 50 µM, concentration was reduced (6: 5 µM; 9: 30 µM). Fragments 5 and 11 revealed a tendency for HNF4α modulation at 50 µM and were subsequently characterized at 100 µM. Additionally, the primary hits were further validated in control experiments involving the potent, ligand-independent transcriptional activator Gal4–VP16 to replace Gal4–HNF4α with otherwise identical assay settings and test compound concentrations (Table 1). Like Gal4–HNF4α, Gal4–VP16 has high constitutive transcriptional inducer activity but is not responsive to ligands. Thus, fragments affecting reporter activity in the Gal4–VP16 setting likely modulate non-specific effects. Fragments 4–7 were confirmed as HNF4α agonists and fragments 9 and 10 exhibited preliminarily validated inverse HNF4α agonism.

Dose-response profiling (Table 2, Figure 3) revealed 6 as the strongest and most potent HNF4α agonist with an EC_{50} value of 5.8 µM and a high 6.1-fold maximum activation efficacy. Fragments 4 (EC_{50} = 15 µM, 5.6-fold act.) and 7 (EC_{50} = 31 µM, 3.8-fold act.) comprised slightly weaker agonist potencies than 6, while fragment 5 (EC_{50} > 100 µM) was considerably less active. The inverse agonists

| ID | Structure | Primary Screen (Fold Act., 50 µM) | Follow-up HNF4α | VP16 Control | HNF4α vs. VP16 |
|----|-----------|----------------------------------|----------------|-------------|---------------|
| 6  | ![Structure](image) | 5.48 | 2.4 ± 0.5 (5 µM) | 1.1 ± 0.1 (5 µM) | \( p = 0.0034 \) (**) |
| 7  | ![Structure](image) | 2.36 | 3.0 ± 0.3 (50 µM) | 1.4 ± 0.1 (50 µM) | \( p < 0.0001 \) (***) |
| 8  | ![Structure](image) | 2.09 | 1.1 ± 0.2 (50 µM) | 0.92 ± 0.07 (50 µM) | n.s. |
| 9  | ![Structure](image) | 0.54 | 0.6 ± 0.1 (30 µM) | 1.2 ± 0.2 (30 µM) | \( p < 0.0001 \) (***) |
| 10 | ![Structure](image) | 0.63 | 0.75 ± 0.05 (50 µM) | 1.1 ± 0.2 (50 µM) | \( p = 0.0057 \) (**) |
| 11 | ![Structure](image) | 0.32 | 0.21 ± 0.03 (100 µM) | 0.21 ± 0.02 (100 µM) | n.s. |
9 (IC$_{50}$ = 8 µM) and 10 (IC$_{50}$ = 24 µM) demonstrated low micromolar activity, and both diminished remaining HNF4$\alpha$ activity by approximately half.

Table 2. Validated HNF4$\alpha$ ligands with control experiment HNF4$\alpha$ modulatory activity and binding affinity to the recombinant HNF4$\alpha$ ligand-binding domain (LBD). EC$_{50}$ and IC$_{50}$ values were calculated from dose–response curves and are the mean ± SD of at least four biologically independent repeats in duplicates. Fold and remaining (rem.) activation (act.) refer to the maximum fold increase or decrease in reporter activity relative to 0.1% DMSO. Binding was determined by isothermal titration calorimetry (ITC). n.d.—not determined

| ID | Structure | HNF4$\alpha$ Ligand Type | Validated HNF4$\alpha$ Modulation | HNF4$\alpha$ LBD Binding |
|----|-----------|-------------------------|-------------------------------|--------------------------|
| 4  | ![Structure](image1) | Agonist | EC$_{50}$ 15 ± 1 µM 5.6 ± 0.3-fold act. | no/weak binding |
| 5  | ![Structure](image2) | Agonist | EC$_{50}$ > 100 µM | n.d. |
| 6  | ![Structure](image3) | Agonist | EC$_{50}$ 5.8 ± 0.6 µM 6.1 ± 0.7-fold act. | no binding |
| 7  | ![Structure](image4) | Agonist | EC$_{50}$ 31 ± 8 µM 3.8 ± 0.6-fold act. | K$_{d}$ 7 µM |
| 9  | ![Structure](image5) | Inverse agonist | IC$_{50}$ 8 ± 2 µM 0.57 ± 0.04 rem. act. | K$_{d}$ 0.3 µM |
| 10 | ![Structure](image6) | Inverse agonist | IC$_{50}$ 24 ± 5 µM 0.65 ± 0.05 rem. act. | K$_{d}$ 1.7 µM |

To capture HNF4$\alpha$ modulation by 4, 6, 7, 9, and 10 in a more physiological setting, we treated HNF4$\alpha$-expressing [19] human hepatocytes (HepG2) with the HNF4$\alpha$ modulators and then determined the mRNA expression levels of the HNF4$\alpha$-regulated gene fructose-1,6-bisphosphatase 1 (FBP1) [19] by quantitative real-time PCR (qRT-PCR). In accordance with its activity in the Gal4-HNF4$\alpha$ assay, the most active HNF4$\alpha$ activator 6 significantly promoted FBP1 expression in HepG2 cells. The less potent agonists 4 and 7 revealed a tendency to enhanced FBP1 mRNA levels. The inverse HNF4$\alpha$ agonists 9 and 10 robustly decreased FBP1 expression, confirming their activity observed in the screening system as well. These results further validate cellular HNF4$\alpha$ modulation by 4, 6, 7, 9, and 10 and demonstrate that these compounds can also be used as initial tools to study HNF4$\alpha$ function in native settings.

For a preliminary quality assessment of this validated HNF4$\alpha$ ligand collection as a starting matter for medicinal chemistry, we calculated key physicochemical features and ligand-efficiency metrics [20,21] (Table 3). As feasibly expected from their chemical structures, the HNF4$\alpha$ agonists 6 and 7 comprised favorably low lipophilicity with low predicted logP values. Fragment 7 possessed the highest ligand efficiency (LE) owing to its small size but also a preferable size-independent ligand
efficiency (SILE). Fragment 6, due to its exceptional polarity, was superior regarding lipophilic ligand efficiency (LLE). Both inverse HNF4α agonists 9 and 10 revealed acceptable lipophilicity with predicted logP values of 3–4. LE, LLE, and SILE were comparable for both compounds and favorably high for fragment-like screening hits.

Figure 3. In vitro characterization of HNF4α modulators 4, 6, 7, 9, and 10. (a) Dose–response curves of 4, 6, 7, 9, and 10 on Gal4-HNF4α (mean ± S.E.M.; n ≥ 4). (b) Effects of 4, 6, 7, 9, and 10 on mRNA expression of fructose-1,6-bisphosphatase 1 (FBP1) in human hepatocytes (HepG2). HNF4α activators 4, 6, and 7 promoted FBP1 expression, while the inverse HNF4α agonists 9 and 10 decreased FBP1 mRNA levels. Data are the mean ± S.E.M. mRNA levels determined by qRT-PCR and analyzed by the 2−ΔΔCt method; n = 3. (c) Control experiments on Gal4-VP16 (boxplots show mean, min.-max.; n ≥ 4). (d) Chemical structures of 4, 6, 7, 9, and 10. * p < 0.05, ** p < 0.01, *** p < 0.001 (t-test).

Table 3. Calculated lipophilicity and ligand efficiency metrics of HNF4α modulators. LogP and logS were retrieved from the ALOGPS 2.1 resource [20]. Ligand efficiency (LE), lipophilic ligand efficiency (LLE), and size-independent ligand efficiency (SILE) were calculated as described in Reference [21].

| ID | HNF4α Activity | LogP | LogS | LE | LLE | SILE |
|----|----------------|------|------|----|-----|------|
| 4  | pEC50 4.8      | 4.13 | -3.72| 0.39| 0.69| 2.1  |
| 5  | pEC50 < 4      | 4.84 | -5.50| <0.32| <0  | <1.7 |
| 6  | pEC50 5.2      | -2.45| -1.30| 0.42| 7.7 | 2.2  |
| 7  | pEC50 4.5      | -0.19| -0.95| 1.03| 4.7 | 2.6  |
| 9  | pIC50 5.1      | 3.77 | -2.85| 0.44| 1.3 | 2.2  |
| 10 | pIC50 4.6      | 3.01 | -3.65| 0.40| 1.6 | 2.0  |

To orthogonally confirm direct interaction between HNF4α and the identified hits, we determined the binding of 4, 6, 7, 9, and 10 to the recombinant HNF4α LBD protein by isothermal titration calorimetry (ITC). In line with the nuclear receptor’s mode of action [3], we observed dimerization of
the HNF4α LBD protein and dimer dissociation upon dilution, which hindered inverse ITC experiments. Fragments 4, 6, 7, 9, and 10 were, therefore, titrated to the HNF4α LBD (Figure 4). Binding of 5 was not studied due to its weak potency observed in the cell-based assay. The ITC results indicated very weak HNF4α binding of 4 and revealed no proper binding isotherm for 6. According to this observation, the effects of 6 on HNF4α activity in the Gal4-HNF4α assay and in HepG2 cells seem to be mediated by indirect pathways and might, for example, involve HNF4α activation by phosphorylation. Since the control experiments on Gal4-VP16 revealed no unspecific effects of 6 and since 6 caused marked upregulation of the HNF4α-regulated FBP1 in hepatocytes, its activity still appears HNF4α-mediated. Current evidence, however, does not support direct HNF4α agonism of 6, and further studies are needed to elucidate the mechanism by which the compound promotes HNF4α activity. For fragments 7, 9, and 10, ITC experiments clearly demonstrated their binding with micromolar binding affinities (7: \( K_d \approx 7 \, \mu M \); 9: \( K_d \approx 0.3 \, \mu M \); 10: \( K_d \approx 1.7 \, \mu M \)), orthogonally validating their direct effect on HNF4α modulation. In addition, fragment 4 likely activated the nuclear receptor through interaction with the LBD despite weak binding affinity and 5 was another weak HNF4α activator according to the cellular experiments.

3. Discussion

Our systematic screening yielded a considerable hit-rate, leading to the discovery of three fully validated HNF4α ligands (7, 9, 10) exhibiting low micromolar potencies and binding affinities as well as two additional weaker HNF4α modulators (4, 5). These hits were highly chemically diverse. We observed no preference for certain chemotypes or functional groups and, surprisingly, only a single carboxylate was discovered as HNF4α ligand, although the nuclear receptor is known to bind fatty acids [4] and the screening library comprised 47 (10%) carboxylic acid-containing fragments. In line with the high constitutive transcriptional inducer activity of HNF4α, we observed bidirectional modulation of the nuclear receptor in the screening Gal4–HNF4α assay and in the native cellular setting in HepG2 cells. The active fragments exhibited different types of activity including agonism and inverse agonism, and direct interaction with the HNF4α LBD was confirmed for 7, 9, and 10. The most active compounds 7, 9, and 10, therefore, present as appealing starting points for medicinal chemistry as they offer favorable ligand efficiencies, low molecular weights, and low lipophilicity. Their scaffolds are simple and common, allowing rapid diversification and structure–activity relationship studies.

The ligand-activated transcription factor HNF4α has been found to involve in metabolic balance and cancer development, but, to date, knowledge on its ligands is very limited. Potent modulators for the nuclear receptor are urgently needed to validate its promising therapeutic potential in metabolic diseases and oncology. We disclose three orthogonally validated HNF4α ligands (7, 9, and 10) as high-quality chemical starting matter for medicinal chemistry. Additionally, our results provide further evidence that activity of the poorly studied nuclear receptor HNF4α can be controlled by small-molecule ligands in a bidirectional fashion thus offering great potential as a molecular drug target. Modulatory effects of 4, 6, 7, 9, and 10 on expression levels of the HNF4α-regulated gene FBP1...
in a native cellular setting indicate that this set of HNF4α modulators can also serve as an initial chemogenomic tool for early functional and phenotypic studies. Still, further efforts are needed to develop highly optimized HNF4α ligands as probes to question the therapeutic potential of the nuclear receptor in depth.

4. Materials and Methods

4.1. Hybrid Gal4-HNF4α Reporter Gene Assay

**Plasmids:** The Gal4-fusion receptor plasmid pFA-CMV-hHNF4α-LBD coding for the hinge region and LBD of the canonical isoform of HNF4α (uniprot entry: P41235-1, residues 142-377) was constructed by integrating cDNA fragments obtained from PCR amplification using natural cDNA (purchased as cDNA clone IRCBp5005M2212Q from Source BioScience, Nottingham, UK) as template between the BamHI cleavage site of the pFA-CMV vector (Stratagene, La Jolla, CA, USA) and an afore inserted KpnI cleavage site as described previously [22–24]. The frame and sequence of the fusion plasmid were verified by sequencing. pFR-Luc (Stratagene) was used as reporter plasmid and pRL-SV40 (Promega, Madison, WI, USA) served for normalization of transfection efficiency and cell growth. The Gal4-VP16 [25] expressed from plasmid pECE-SV40-Gal4-VP16 [26] (Addgene, entry 71728, Watertown, MA, USA) was used as a ligand-independent transcriptional inducer for control experiments.

**Assay Procedure:** HEK293T cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) high glucose, supplemented with 10% Fetal Bovine Serum (FCS), sodium pyruvate (1 mM), penicillin (100 U/mL), and streptomycin (100 µg/mL) at 37 °C and 5% CO2. The day before transfection, HEK293T cells were seeded in 96-well plates (3.0 × 10⁴ cells/well). Before transfection, the medium was changed to Opti-MEM without supplements. Transient transfection was carried out using Lipofectamine LTX reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol with pFR-Luc (Stratagene), pRL-SV40 (Promega), and the pFA-CMV-hHNF4α-LBD clone or pECE-SV40-Gal4-VP16 for control experiments. Five hours after transfection, the medium was changed to Opti-MEM supplemented with penicillin (100 U/mL), streptomycin (100 µg/mL), now additionally containing 0.1% DMSO (0.2% in the primary screen) and the respective test compounds or 0.1% DMSO (0.2% in the primary screen) alone as the untreated control. In the primary screening, the core set of the Prestwick Drug Fragment Library (Prestwick Chemical, Illkirch, France) was tested at 50 µM concentration in two biologically independent repeats. In the follow-up and dose-response profiling, each concentration was tested in duplicates in at least three biologically independent repeats. Following overnight (12–14 h) incubation with the test compounds, cells were assayed for luciferase activity using Dual-Glo™ luciferase assay system (Promega) according to the manufacturer’s protocol. Luminescence was measured with a Tecan Spark 10M luminometer (Tecan Group Ltd., Männedorf, Switzerland). Normalization of transfection efficiency and cell growth was done by division of firefly luciferase data by renilla luciferase data and multiplying the value by 1000, resulting in relative light units (RLU). Fold activation was obtained by dividing the mean RLU of test compounds at a respective concentration by the mean RLU of untreated control.

4.2. Recombinant HNF4α LBD Expression and Purification

The LDB domain of HNF4α (aa. 148–377) subcloned into pNIC28-Bsa4 was expressed in *E. coli* Rosetta. The recombinant protein harboring an N-terminal His₆ tag was initially purified by Ni²⁺-affinity chromatography. Size exclusion chromatography was performed using Superdex S75 column (GE Healthcare, Chicago, IL, USA.), and the pure protein was stored in a buffer containing 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.5, 200 mM NaCl, 0.5 mM tris(2-carboxyethyl)phosphine (TCEP), and 5% w/v glycerol.
4.3. Quantification of Human FBP1 mRNA Expression in HepG2 Cells by Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)

HepG2 cells were grown in 12-well plates in DMEM high glucose, supplemented with 10% FCS, sodium pyruvate (1 mM), penicillin (100 U/mL), and streptomycin (100 µg/mL) at 37 °C and 5% CO₂ to approximately 60% confluence. Before incubation with test compounds, cells were kept in MEM supplemented with 1% charcoal-stripped FCS, penicillin (100 U/mL), and streptomycin (100 µg/mL) for 24 h [27]. For gene expression analysis, cells were incubated with 4 (50 µM), 6 (10 µM), 7 (50 µM), 9 (50 µM), 10 (50 µM), or 0.1% DMSO as untreated control in the same medium for 8 h. The cells were then harvested and directly used for RNA extraction by the E.Z.N.A. Total RNA Kit I (R6834-02, Omega Bio-Tek, Inc., Norcross, GA, USA). Three micrograms of total RNA extracted from HepG2 cells were reverse-transcribed into cDNA using the High-Capacity RNA-to-cDNA Kit (4387406, Thermo Fischer Scientific, Inc., Waltham, MA, USA) according to the manufacturer’s protocol. HNF4α-regulated FBP1 expression was evaluated by qRT-PCR analysis with a StepOnePlus System (Life Technologies, Carlsbad, CA, USA) using Power SYBR Green (Life Technologies; 12.5 µL/well). Each sample was set up in duplicates and repeated in three independent experiments. Data were analyzed by the comparative $2^{-\Delta\Delta C_{t}}$ method with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as the reference gene. The following PCR primers were used: hGAPDH [28]: 5′-ATA TGA TTC CAC CCA TGG CA (fw), 5′-GAT GAT GAC CCT TTT GGC TC (rev) and hFBP1 [19]: 5′-AGC CTT CTG AGA AGG ATG CTC (fw), 5′-GTC CAG CAT GAA GCA GTT GAC (rev).

4.4. Isothermal Titration Calorimetry

Isothermal titration calorimetry was performed on an Affinity ITC (TA Instruments, New Castle, DE, USA). The instrument was equilibrated to 25 °C and the stirring rate was set to 75 rpm. HNF4α buffer (20 mM HEPES pH 7.5, 200 mM NaCl, 0.5 mM TCEP, 5% w/v glycerol) with up to 1% DMSO (final concentration) was used for ITC. The recombinant HNF4α LBD protein (10–20 µM, 172 µL) was titrated with fragments (4, 6, 7, 9, 10; 50–200 µM; dissolved in the same buffer). A total of 20-30 injections with a volume of 2.5–4 µL and with an interval of 200–300 s were performed. As a control experiment, HNF4α protein was titrated with buffer, and the buffer was titrated with test compound to detect dissolution artifacts with otherwise identical experimental parameters. Data analysis was performed with NanoAnalyze™ Software (TA Instruments, New Castle, DE, USA.) using an independent binding model.

Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/21/7895/s1. Table S1. All molecular structures of library compounds with associated primary screening data.

Author Contributions: I.M. and S.W. performed the experiments; X.N., J.H., and A.C. contributed materials; D.M. conceptualized and supervised the project and wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875510. The JU receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA and Ontario Institute for Cancer Research, Royal Institution for the Advancement of Learning McGill University, Kungliga Tekniska Hoegskolan, Diamond Light Source Limited.

Acknowledgments: D.M. is grateful for financial support from the Aventis Foundation. The SGC is a registered charity (no: 1097737) that receives funds from AbbVie, Bayer AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genentech, Genome Canada through Ontario Genomics Institute [OGI-196], EU/EFPIA/OICR/McGill/KTH/Diamond, Innovative Medicines Initiative 2 Joint Undertaking [EUBOPEN grant 875510], Janssen, Merck KGaA (aka EMD in Canada and US), Merck & Co (aka MSD outside Canada and US), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome [106169/ZZ14/Z].

Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations

FBP1 fructose-1,6-bisphosphatase 1
HNF4α hepatocyte nuclear factor 4α
LBD Ligand-binding domain
MODY maturity-onset diabetes of the young
RLU relative light units

References

1. Alexander, S.P.; Cidlowski, J.A.; Kelly, E.; Marrion, N.V.; Peters, J.A.; Facenda, E.; Harding, S.D.; Pawson, A.J.; Sharman, J.L.; Southan, C.; et al. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Nuclear hormone receptors. Br. J. Pharmacol. 2017, 174, S208–S224. [CrossRef]

2. Benoit, G.; Cooney, A.; Giguere, V.; Ingraham, H.; Lazar, M.; Muscat, G.; Perlmann, T.; Renaud, J.P.; Schwabe, J.; Sladek, F.; et al. International union of pharmacology. LXVI. Orphan nuclear receptors. Pharmacol. Rev. 2006, 58, 798–836. [CrossRef]

3. Chandra, V.; Huang, P.; Potluri, N.; Wu, D.; Kim, Y.; Rastinejad, F. Multidomain integration in the structure of the HNF-4α nuclear receptor complex. Nature 2013, 495, 394–398. [CrossRef]

4. Yuan, X.; Ta, T.C.; Lin, M.; Evans, J.R.; Dong, Y.; Bolotin, E.; Sherman, M.A.; Forman, B.M.; Sladek, F.M. Identification of an endogenous ligand bound to a native orphan nuclear receptor. PLoS ONE 2009, 4, e5609. [CrossRef] [PubMed]

5. Kiselyuk, A.; Lee, S.H.; Farber-Katz, S.; Zhang, M.; Athavankar, S.; Cohen, T.; Pinkerton, A.B.; Ye, M.; Bushway, P.; Richardson, A.D.; et al. HNF4α antagonists discovered by a high-throughput screen for modulators of the human insulin promoter. Chem. Biol. 2012, 19, 806–818. [CrossRef] [PubMed]

6. Jiang, S.; Tanaka, T.; Iwanari, H.; Hotta, H.; Yamashita, H.; Kumakura, J.; Wanatabe, Y.; Uchiyama, Y.; Aburatani, H.; Hamakubo, T.; et al. Expression and localization of P1 promoter-driven hepatocyte nuclear factor-4α (HNF4α) isoforms in human and rats. Nucl. Recept. 2003, 1, 5. [CrossRef] [PubMed]

7. Chen, L.; Vasoya, R.P.; Toke, N.H.; Parthasarathy, A.; Luo, S.; Chiles, E.; Flores, J.; Gao, N.; Bondet, E.M.; Su, X.; et al. HNF4 Regulates Fatty Acid Oxidation and Is Required for Renewal of Intestinal Stem Cells in Mice. Gastroenterology 2020, 158, 985–999. [CrossRef] [PubMed]

8. Hayhurst, G.P.; Lee, Y.-H.; Lambert, G.; Ward, J.M.; Gonzalez, F.J. Hepatocyte Nuclear Factor 4α (Nuclear Receptor 2A1) Is Essential for Maintenance of Hepatic Gene Expression and Lipid Homeostasis. Mol. Cell. Biol. 2001, 21, 1393–1403. [CrossRef] [PubMed]

9. Gupta, R.K.; Gao, N.; Gorski, R.K.; White, P.; Hardy, O.T.; Rafiq, K.; Brestelli, J.E.; Chen, G.; Stoeckert, C.J.; Kaestner, K.H. Expansion of adult β-cell mass in response to increased metabolic demand is dependent on HNF-4α. Genes Dev. 2007, 21, 756–769. [CrossRef]

10. Warncke, K.; Kummer, S.; Raile, K.; Grulich-Henn, J.; Woelflé, J.; Steichen, E.; Prinz, N.; Holl, R.W. Frequency and Characteristics of MODY 1 (HNF4A Mutation) and MODY 5 (HNF1B Mutation): Analysis from the DPV Database. J. Clin. Endocrinol. Metab. 2018, 104, 845–855. [CrossRef]

11. Ahn, S.H.; Shah, Y.M.; Inoue, J.; Morimura, K.; Kim, I.; Yim, S.H.; Lambert, G.; Kurotani, R.; Nagashima, K.; Gonzalez, F.J.; et al. Hepatocyte nuclear factor 4α in the intestinal epithelial cells protects against inflammatory bowel disease. Inflamm. Bowel Dis. 2008, 14, 908–920. [CrossRef] [PubMed]

12. Ma, Y.; Wei, X.; Wu, Z. HNF-4α promotes multidrug resistance of gastric cancer cells through the regulation of cell apoptosis. Oncol. Lett. 2017, 14, 6477–6484. [CrossRef] [PubMed]

13. Kwon, S.M.; Jung, Y.Y.; Hwang, C.J.; Park, M.H.; Yoon, N.Y.; Kim, T.M.; Yu, J.M.; Kim, D.H.; Seo, D.W.; Youn, H.S.; et al. Anti-cancer effect of N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2,3-dihydronaphtho[1,2-b]furan-2-carboxamide, a novel synthetic compound. Mol. Carcinog. 2016, 55, 659–670. [CrossRef] [PubMed]

14. Gupta, R.K.; Kaestner, K.H. HNF-4α: From MODY to late-onset type 2 diabetes. Trends Mol. Med. 2004, 10, 521–524. [CrossRef]

15. Anik, A.; Çatlı, G.; Abaci, A.; Böber, E. Maturity-onset diabetes of the young (MODY): An update. J. Pediatr. Endocrinol. Metab. 2015, 28, 251–263. [CrossRef]
16. Colclough, K.; Bellanne-Chantelot, C.; Saint-Martin, C.; Flanagan, S.E.; Ellard, S. Mutations in the Genes Encoding the Transcription Factors Hepatocyte Nuclear Factor 1 Alpha and 4 Alpha in Maturity-Onset Diabetes of the Young and Hyperinsulinemic Hypoglycemia. *Hum. Mutat.* 2013, 34, 669–685. [CrossRef]

17. Le Guével, R.; Oger, F.; Lecorgne, A.; Dudasova, Z.; Chevance, S.; Bondon, A.; Barath, P.; Simonneaux, G.; Salbert, G. Identification of small molecule regulators of the nuclear receptor HNF4α based on naphthofuran scaffolds. *Bioorg. Med. Chem.* 2009, 17, 7021–7030. [CrossRef]

18. Heering, J.; Merk, D. Hybrid Reporter Gene Assays: Versatile In Vitro Tools to Characterize Nuclear Receptor Modulators. In *Methods in Molecular Biology* (Clifton, N.J.); Humana: New York, NY, USA, 2019; Volume 1966, pp. 175–192.

19. Wattanavanitchakorn, S.; Rojvirat, P.; Chavalit, T.; MacDonald, M.J.; Jitrapakdee, S. CCAAT-enhancer binding protein-α (C/EBPα) and hepatocyte nuclear factor 4α (HNF4α) regulate expression of the human fructose-1,6-bisphosphatase 1 (FBP1) gene in human hepatocellular carcinoma HepG2 cells. *PLoS ONE* 2018, 13, e0194252. [CrossRef]

20. Tetko, I.V.; Tanchuk, V.Y. Application of associative neural networks for prediction of lipophilicity in ALOGPS 2.1 program. *J. Chem. Inf. Comput. Sci.* 2002, 42, 1136–1145. [CrossRef]

21. Hopkins, A.L.; Keserü, G.M.; Leeson, P.D.; Rees, D.C.; Reynolds, C.H. The role of ligand efficiency metrics in drug discovery. *Nat. Rev. Drug Discov.* 2014, 13, 105–121. [CrossRef]

22. Flesch, D.; Cheung, S.-Y.; Schmidt, J.; Gabler, M.; Heitel, P.; Kramer, J.S.; Kaiser, A.; Hartmann, M.; Lindner, M.; Lüddens-Dämgen, K.; et al. Non-acidic farnesoid X receptor modulators. *J. Med. Chem.* 2017, 60, 7199–7205. [CrossRef] [PubMed]

23. Schmidt, J.; Rotter, M.; Weiser, T.; Wittmann, S.; Weizel, L.; Kaiser, A.; Heering, J.; Goebel, T.; Angioni, C.; Wurglics, M.; et al. A dual modulator of farnesoid X receptor and soluble epoxide hydrolase to counter nonalcoholic steatohepatitis. *J. Med. Chem.* 2017, 60, 7703–7724. [CrossRef]

24. Willems, S.; Kilu, W.; Ni, X.; Chaikuad, A.; Knapp, S.; Heering, J.; Merk, D. The orphan nuclear receptor Nurr1 is responsive to non-steroidal anti-inflammatory drugs. *Commun. Chem.* 2020, 3, 85. [CrossRef]

25. Sadowski, I.; Ma, J.; Triezenberg, S.; Ptashne, M. GAL4-VP16 is an unusually potent transcriptional activator. *Nature* 1988, 335, 563–564. [CrossRef] [PubMed]

26. Budzynski, M.A.; Puustinen, M.C.; Joutsen, J.; Sistonen, L. Uncoupling Stress-Inducible Phosphorylation of Heat Shock Factor 1 from Its Activation. *Mol. Cell. Biol.* 2015, 35, 2530–2540. [CrossRef] [PubMed]

27. Schmidt, J.; Klingler, F.-M.; Proschak, E.; Steinhilber, D.; Schubert-Zsilavecz, M.; Merk, D. NSAIDs Ibuprofen, Indometacin, and Diclofenac do not interact with Farnesoid X Receptor. *Sci. Rep.* 2015, 5, 14782. [CrossRef]

28. Merk, D.; Lamers, C.; Ahmad, K.; Carrasco Gomez, R.; Schneider, G.; Steinhilber, D.; Schubert-Zsilavecz, M. Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: Development of a highly potent partial farnesoid X receptor agonist. *J. Med. Chem.* 2014, 57, 8035–8055. [CrossRef] [PubMed]

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).